JP7074761B2 - 治療用デンドリマー - Google Patents

治療用デンドリマー Download PDF

Info

Publication number
JP7074761B2
JP7074761B2 JP2019543376A JP2019543376A JP7074761B2 JP 7074761 B2 JP7074761 B2 JP 7074761B2 JP 2019543376 A JP2019543376 A JP 2019543376A JP 2019543376 A JP2019543376 A JP 2019543376A JP 7074761 B2 JP7074761 B2 JP 7074761B2
Authority
JP
Japan
Prior art keywords
dendrimer
pharmaceutically acceptable
acceptable salt
formula
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019543376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508985A5 (enExample
JP2020508985A (ja
Inventor
ウィリアム・マックール
マリアン・バーニス・アシュフォード
イアン・グラント
エドワード・ジョン・ヘネシー
ジョン・ポール・セクリスト
デイビッド・オーウェン
ブライアン・ケリー
マイケル・ジャニス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2020508985A publication Critical patent/JP2020508985A/ja
Publication of JP2020508985A5 publication Critical patent/JP2020508985A5/ja
Application granted granted Critical
Publication of JP7074761B2 publication Critical patent/JP7074761B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Prostheses (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2019543376A 2017-02-22 2018-02-22 治療用デンドリマー Expired - Fee Related JP7074761B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762461983P 2017-02-22 2017-02-22
US62/461,983 2017-02-22
US201762488151P 2017-04-21 2017-04-21
US62/488,151 2017-04-21
US201762591823P 2017-11-29 2017-11-29
US62/591,823 2017-11-29
PCT/EP2018/054420 WO2018154004A1 (en) 2017-02-22 2018-02-22 Therapeutic dendrimers

Publications (3)

Publication Number Publication Date
JP2020508985A JP2020508985A (ja) 2020-03-26
JP2020508985A5 JP2020508985A5 (enExample) 2021-03-11
JP7074761B2 true JP7074761B2 (ja) 2022-05-24

Family

ID=61386833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019543376A Expired - Fee Related JP7074761B2 (ja) 2017-02-22 2018-02-22 治療用デンドリマー

Country Status (23)

Country Link
US (4) US10314920B2 (enExample)
EP (1) EP3585441A1 (enExample)
JP (1) JP7074761B2 (enExample)
KR (2) KR20230093346A (enExample)
CN (2) CN110312531A (enExample)
AU (1) AU2018223149B2 (enExample)
BR (1) BR112019016409A2 (enExample)
CA (1) CA3053069A1 (enExample)
CL (1) CL2019002240A1 (enExample)
CO (1) CO2019009722A2 (enExample)
CR (1) CR20190361A (enExample)
DO (1) DOP2019000204A (enExample)
EC (1) ECSP19056271A (enExample)
IL (1) IL268648B (enExample)
JO (1) JOP20190191B1 (enExample)
MX (1) MX2019009442A (enExample)
NI (1) NI201900088A (enExample)
PE (1) PE20191660A1 (enExample)
PH (1) PH12019501896A1 (enExample)
SG (1) SG11201907334QA (enExample)
TW (1) TWI773730B (enExample)
UA (1) UA125655C2 (enExample)
WO (1) WO2018154004A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
TWI856967B (zh) * 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
CN113056469B (zh) * 2018-11-20 2025-05-23 星法马私人有限公司 治疗性树状聚体
EP3965567B1 (en) 2019-05-07 2023-07-05 Syddansk Universitet Mechanism for dispensing biological material
CN114585389A (zh) * 2019-09-26 2022-06-03 星法马私人有限公司 治疗性树枝状大分子
CA3163886A1 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
BR112022012283A2 (pt) 2019-12-20 2022-08-30 Recurium Ip Holdings Llc Combinações
WO2021213492A1 (zh) * 2020-04-24 2021-10-28 上海森辉医药有限公司 一类载药的大分子及其制备方法
JP2023522984A (ja) 2020-04-24 2023-06-01 アシュバッタ セラピューティクス， インコーポレイテッド 重症急性呼吸促迫症候群の処置のためのデンドリマー組成物および方法
CN115697967B (zh) * 2020-07-10 2024-10-22 江苏恒瑞医药股份有限公司 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用
JP7880863B2 (ja) 2020-08-25 2026-06-26 上海森輝医薬有限公司 薬剤を担持する高分子及びその調製方法
US20230263900A1 (en) * 2020-08-31 2023-08-24 Starpharma Pty Ltd. Dendrimer-drug conjugate
CN115260152A (zh) * 2021-04-30 2022-11-01 江苏恒瑞医药股份有限公司 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532718A (ja) 2010-08-06 2013-08-19 アストラゼネカ アクチボラグ Ｎ−アシルスルホンアミドアポトーシスプロモーター
JP2014520105A (ja) 2011-06-06 2014-08-21 スターファーマ・ピーティーワイ・リミテッド 高分子

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4410688A (en) * 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
HUE031341T2 (hu) * 2005-10-25 2017-07-28 Starpharma Pty Ltd Ellenõrzött sztöchiometriájú makromolekuláris vegyületek
WO2007082331A1 (en) 2006-01-20 2007-07-26 Starpharma Pty Limited Modified macromolecule
US9127130B2 (en) * 2006-08-11 2015-09-08 Starpharma Pty Ltd. Polylysine dendrimer contrast agent
WO2008017125A1 (en) * 2006-08-11 2008-02-14 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
AU2007319209B2 (en) 2006-11-15 2012-04-19 Genentech, Inc. Arylsulfonamide compounds
US9283302B2 (en) 2011-12-16 2016-03-15 Cormatrix Cardiovascular, Inc. Extracellular matrix encasement structures and methods
WO2009036035A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
CN102076331B (zh) 2008-06-26 2013-12-18 普罗林科斯有限责任公司 具有可控的药物释放速率的前药和药物-大分子轭合物
US8216549B2 (en) * 2008-07-25 2012-07-10 National Health Research Institutes Method for making a ligand-quantum dot conjugate
NZ614305A (en) 2008-12-05 2015-03-27 Abbvie Inc Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
ES2546294T7 (es) 2009-05-26 2024-06-06 Abbvie Ireland Unlimited Co Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
US20120269721A1 (en) * 2009-10-12 2012-10-25 The Regents Of The University Of California Targeted nanoclusters and methods of their use
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
WO2011140376A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from dendrimers
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
WO2015035446A1 (en) * 2013-09-10 2015-03-19 Starpharma Pty Ltd Macromolecules of dendrimer-platinum conjugates
EP3152248B1 (en) * 2014-06-06 2019-10-09 Starpharma Pty Ltd Dendrimer-drug conjugates
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
TWI856967B (zh) * 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532718A (ja) 2010-08-06 2013-08-19 アストラゼネカ アクチボラグ Ｎ−アシルスルホンアミドアポトーシスプロモーター
JP2014520105A (ja) 2011-06-06 2014-08-21 スターファーマ・ピーティーワイ・リミテッド 高分子

Also Published As

Publication number Publication date
BR112019016409A2 (pt) 2020-04-07
CL2019002240A1 (es) 2019-11-29
NI201900088A (es) 2020-03-18
US11717574B2 (en) 2023-08-08
SG11201907334QA (en) 2019-09-27
WO2018154004A1 (en) 2018-08-30
JOP20190191A1 (ar) 2019-08-08
MX2019009442A (es) 2019-10-09
US20180264127A1 (en) 2018-09-20
US20200069810A1 (en) 2020-03-05
CO2019009722A2 (es) 2019-09-18
PE20191660A1 (es) 2019-11-11
US20240115716A1 (en) 2024-04-11
CA3053069A1 (en) 2018-08-30
CN117582521A (zh) 2024-02-23
IL268648A (en) 2019-10-31
TW201841659A (zh) 2018-12-01
UA125655C2 (uk) 2022-05-11
WO2018154004A9 (en) 2018-12-27
US10888624B2 (en) 2021-01-12
TWI773730B (zh) 2022-08-11
CN110312531A (zh) 2019-10-08
AU2018223149B2 (en) 2021-04-01
KR20230093346A (ko) 2023-06-27
KR102544033B1 (ko) 2023-06-14
EP3585441A1 (en) 2020-01-01
US20210060172A1 (en) 2021-03-04
CR20190361A (es) 2019-09-24
KR20190112330A (ko) 2019-10-04
US10314920B2 (en) 2019-06-11
PH12019501896A1 (en) 2019-10-21
JP2020508985A (ja) 2020-03-26
AU2018223149A1 (en) 2019-10-03
DOP2019000204A (es) 2019-08-30
IL268648B (en) 2022-04-01
ECSP19056271A (es) 2019-08-30
JOP20190191B1 (ar) 2024-04-16

Similar Documents

Publication Publication Date Title
US11717574B2 (en) Therapeutic dendrimers
KR102388208B1 (ko) 암을 치료하기 위한 거대 환형 mcl1 억제제
JP6423425B2 (ja) 結晶性ブロモドメインインヒビター
ES2523999T3 (es) Dispersiones sólidas que contienen inhibidores de cinasas
KR102124715B1 (ko) 암의 치료를 위한 bcl-2 억제제 및 mek 억제제의 조합물
CN102802607A (zh) 含有凋亡促进剂的固态分散体
WO2018202910A1 (en) Combination of antibiotic and bcl-2 inhibitor and uses thereof
CA3108638A1 (en) Conjugates for use in methods of treating cancer
CN114853753B (zh) 吡啶并[1,2-a]嘧啶酮类似物及其在制备FGFR抑制剂中的用途
HK40108454A (en) Therapeutic dendrimers
EA041072B1 (ru) Терапевтические дендримеры
HK40013356A (en) Therapeutic dendrimers
JP5727598B2 (ja) キナーゼ阻害剤の結晶形
EP3837017A1 (en) Dendrimer formulations
JP5711814B2 (ja) キナーゼ阻害剤の結晶形態
US20170197980A1 (en) N-(4-phenyl)-n'-(3-fluorophenyl)urea docusate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220426

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220512

R150 Certificate of patent or registration of utility model

Ref document number: 7074761

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees